文献速递湿疹皮炎与荨麻疹

血液转录组特征作为阿布昔替尼治疗特应性皮炎疗效的指标与预测因子

Blood Transcriptome Signature as Indicator and Predictor for Efficacy of Abrocitinib in Treatment of Atopic Dermatitis.
PubMed 文献 · J Invest Dermatol · 2025-03-07

本研究对31例特应性皮炎患者在接受每日100mg阿布昔替尼治疗前及治疗4周、12周时进行血细胞mRNA测序,发现治疗4周时血液转录组快速正常化,包括Th2、Th1和嗜酸性粒细胞下调及1型调节性T细胞增多,12周轻微反弹;基线嗜酸性粒细胞计数较高预示转录组正常化更明显。加权基因共表达网络分析识别出疗效相关基因模块,构建了5基因疗效预测模型并在另一独立30例患者队列中验证。

要点

  • 阿布昔替尼治疗4周即诱导AD血液转录组快速且广泛正常化。
  • 基线嗜酸性粒细胞计数较高者转录组正常化程度更明显。
  • 5基因(PLIN2、CAT、CLC、RAB44、SMPD3)模型可预测疗效并在独立队列验证。

核心结论

  • 阿布昔替尼治疗使AD患者失调的血液转录组快速且广泛正常化,且与临床疗效相关。

研究设计与样本

  • 对31例AD患者在接受每日100mg阿布昔替尼治疗基线及4周、12周时进行血细胞mRNA测序,并做差异基因表达、免疫浸润和加权基因共表达网络分析及转录组与临床特征相关性分析。
  • 疗效预测模型在另一独立30例接受阿布昔替尼治疗的AD患者队列中验证。

主要发现

  • 阿布昔替尼治疗显著改善AD临床体征。
  • 治疗4周时血液转录组正常化,包括Th2、Th1和嗜酸性粒细胞下调及1型调节性T细胞丰度增加,12周时轻微反弹。
  • 基线嗜酸性粒细胞计数较高预示更明显的转录组正常化。
  • 加权基因共表达网络分析识别出疗效相关基因模块,并构建5基因(PLIN2、CAT、CLC、RAB44、SMPD3)疗效预测模型。

临床怎么用

  • 基线嗜酸性粒细胞计数可能作为阿布昔替尼治疗AD转录组正常化程度的预测指标。
  • 5基因疗效预测模型有望用于预测阿布昔替尼治疗AD的疗效,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with atopic dermatitis (AD) exhibit significant blood transcriptome alterations, reflecting systemic inflammation. The effects of abrocitinib, a Jak1 inhibitor, on the blood transcriptome of AD remain unclear. This study aimed to investigate abrocitinib's effects on the blood transcriptome in patients with AD and identify transcriptomic predictors of treatment efficacy. Blood cell mRNA sequencing was conducted on 31 patients with AD at baseline and 4 and 12 weeks of 100 mg abrocitinib daily treatment. Differential gene expression, immune infiltration, and weighted gene coexpression network analyses were performed, along with correlation analysis of transcriptomic data and clinical traits. We observed that abrocitinib treatment significantly improved clinical signs of AD. Correspondingly, blood transcriptome normalization, including downregulation of T helper 2, T helper 1, and eosinophil and an increase in type 1 regulatory T-cell abundance, rapidly occurred by week 4, with slight rebound by week 12. Higher baseline eosinophil counts predicted greater transcript normalization. Weighted gene coexpression network analyses identified an efficacy-related gene module, leading to a 5-gene (PLIN2, CAT, CLC, RAB44, and SMPD3) efficacy-predictive model, which was validated in another independent cohort of 30 patients with AD treated with abrocitinib. In conclusion, abrocitinib treatment resulted in rapid and extensive normalization of the dysregulated blood transcripts in AD, which was associated with its clinical efficacy.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Yin H, Li Z, et al. Blood Transcriptome Signature as Indicator and Predictor for Efficacy of Abrocitinib in Treatment of Atopic Dermatitis. J Invest Dermatol. 2025. PMID: 40058571. doi:10.1016/j.jid.2025.02.145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。